Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

Central European Institute of Technology Masaryk University Brno 625 00 Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno 656 53 Czech Republic

Department of Neurosurgery University Hospital Brno Brno 625 00 Czech Republic

Department of Radiation Oncology Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno 656 53 Czech Republic

Faculty of Medicine Masaryk University Brno 625 00 Czech Republic

See more in PubMed

De Robles P., Fiest K.M., Frolkis A.D., Pringsheim T., Atta C., St Germaine-Smith C., Day L., Lam D., Jette N. The worldwide incidence and prevalence of primary brain tumors: A systematic review and meta-analysis. Neuro. Oncol. 2015;17:776–783. doi: 10.1093/neuonc/nou283. PubMed DOI PMC

Nayak L., Lee E.Q., Wen P.Y. Epidemiology of brain metastases. Curr. Oncol. Rep. 2012;14:48–54. doi: 10.1007/s11912-011-0203-y. PubMed DOI

Altieri R., Agnoletti A., Quattrucci F., Garbossa D., Calamo Specchia F.M., Bozzaro M., Fornaro R., Mencarani C., Lanotte M., Spaziante R., et al. Molecular biology of gliomas: Present and future challenges. Transl. Med. UniSa. 2014;10:29–37. PubMed PMC

Ostrom Q.T., Bauchet L., Davis F.G., Deltour I., Fisher J.L., Langer C.E., Pekmezci M., Schwartzbaum J.A., Turner M.C., Walsh K.M., et al. Response to “the epidemiology of glioma in adults: A ‘state of the science’ review”. Neuro Oncol. 2015;17:624–626. doi: 10.1093/neuonc/nov022. PubMed DOI PMC

Sahm F., Schrimpf D., Stichel D., Jones D.T.W., Hielscher T., Schefzyk S., Okonechnikov K., Koelsche C., Reuss D.E., Capper D., et al. DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis. Lancet Oncol. 2017;18:682–694. doi: 10.1016/S1470-2045(17)30155-9. PubMed DOI

Sanson M., Kalamarides M. Epigenetics: A new tool for meningioma management? Lancet Oncol. 2017;18:569–570. doi: 10.1016/S1470-2045(17)30153-5. PubMed DOI

Shaikh N., Dixit K., Raizer J. Recent advances in managing/understanding meningioma. F1000Research. 2018;7 doi: 10.12688/f1000research.13674.1. PubMed DOI PMC

Kamar F.G., Posner J.B. Brain metastases. Semin. Neurol. 2010;30:217–235. doi: 10.1055/s-0030-1255225. PubMed DOI

Kopkova A., Sana J., Fadrus P., Slaby O. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clin. Chem. Lab. Med. 2018;56:869–879. doi: 10.1515/cclm-2017-0958. PubMed DOI

Shalaby T., Grotzer M.A. Tumor-Associated CSF MicroRNAs for the Prediction and Evaluation of CNS Malignancies. Int. J. Mol. Sci. 2015;16:29103–29119. doi: 10.3390/ijms161226150. PubMed DOI PMC

Sana J., Hajduch M., Michalek J., Vyzula R., Slaby O. MicroRNAs and glioblastoma: Roles in core signalling pathways and potential clinical implications. J. Cell. Mol. Med. 2011;15:1636–1644. doi: 10.1111/j.1582-4934.2011.01317.x. PubMed DOI PMC

Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010;56:1733–1741. doi: 10.1373/clinchem.2010.147405. PubMed DOI PMC

Baraniskin A., Kuhnhenn J., Schlegel U., Maghnouj A., Zollner H., Schmiegel W., Hahn S., Schroers R. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 2012;14:29–33. doi: 10.1093/neuonc/nor169. PubMed DOI PMC

Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E., Smolsky M., Kim R.Y., Saria M.G., Pastorino S., Kesari S., et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012;14:689–700. doi: 10.1093/neuonc/nos074. PubMed DOI PMC

Drusco A., Bottoni A., Lagana A., Acunzo M., Fassan M., Cascione L., Antenucci A., Kumchala P., Vicentini C., Gardiman M.P., et al. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget. 2015;6:20829–20839. doi: 10.18632/oncotarget.4096. PubMed DOI PMC

Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009;10:704–714. doi: 10.1038/nrg2634. PubMed DOI PMC

Mishra P.J. MicroRNAs as promising biomarkers in cancer diagnostics. Biomark. Res. 2014;2:19. doi: 10.1186/2050-7771-2-19. PubMed DOI PMC

Qu K., Lin T., Pang Q., Liu T., Wang Z., Tai M., Meng F., Zhang J., Wan Y., Mao P., et al. Extracellular mirna-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget. 2016;7:33994–34010. doi: 10.18632/oncotarget.9188. PubMed DOI PMC

Regazzo G., Terrenato I., Spagnuolo M., Carosi M., Cognetti G., Cicchillitti L., Sperati F., Villani V., Carapella C., Piaggio G., et al. A restricted signature of serum mirnas distinguishes glioblastoma from lower grade gliomas. J. Exp. Clin. Cancer Res. 2016;35:124. doi: 10.1186/s13046-016-0393-0. PubMed DOI PMC

Guan Y., Mizoguchi M., Yoshimoto K., Hata N., Shono T., Suzuki S.O., Araki Y., Kuga D., Nakamizo A., Amano T., et al. Mirna-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin. Cancer Res. 2010;16:4289–4297. doi: 10.1158/1078-0432.CCR-10-0207. PubMed DOI

Guan Y., Chen L., Bao Y., Qiu B., Pang C., Cui R., Wang Y. High mir-196a and low mir-367 cooperatively correlate with unfavorable prognosis of high-grade glioma. Int. J. Clin. Exp. Pathol. 2015;8:6576–6588. PubMed PMC

Yan W., Li R., Liu Y., Yang P., Wang Z., Zhang C., Bao Z., Zhang W., You Y., Jiang T. Microrna expression patterns in the malignant progression of gliomas and a 5-microrna signature for prognosis. Oncotarget. 2014;5:12908–12915. doi: 10.18632/oncotarget.2679. PubMed DOI PMC

Visani M., de Biase D., Marucci G., Cerasoli S., Nigrisoli E., Bacchi Reggiani M.L., Albani F., Baruzzi A., Pession A. Expression of 19 micrornas in glioblastoma and comparison with other brain neoplasia of grades i-iii. Mol. Oncol. 2014;8:417–430. doi: 10.1016/j.molonc.2013.12.010. PubMed DOI PMC

Zhang W., Zhao W., Ge C., Li X., Yang X., Xiang Y., Sun Z. Decreased let-7b is associated with poor prognosis in glioma. Medicine. 2019;98:e15784. doi: 10.1097/MD.0000000000015784. PubMed DOI PMC

Malzkorn B., Wolter M., Liesenberg F., Grzendowski M., Stuhler K., Meyer H.E., Reifenberger G. Identification and functional characterization of micrornas involved in the malignant progression of gliomas. Brain Pathol. 2010;20:539–550. doi: 10.1111/j.1750-3639.2009.00328.x. PubMed DOI PMC

Kopkova A., Sana J., Fadrus P., Machackova T., Vecera M., Vybihal V., Juracek J., Vychytilova-Faltejskova P., Smrcka M., Slaby O. MicroRNA isolation and quantification in cerebrospinal fluid: A comparative methodical study. PLoS ONE. 2018;13:e0208580. doi: 10.1371/journal.pone.0208580. PubMed DOI PMC

MicroRNA Analysis in Meningiomas with Different Degrees of Tissue Stiffness: A Potential Tool for Effective Preoperative Planning

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas